Precipio Inc (PRPO)

$28.00 +0.97 (3.57%)
Market Cap 48.21M
Revenue (ttm) 24.05M
Net Income (ttm) -360,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1.50%
Debt to Equity Ratio 0.01
Volume 15,500
Avg Vol 25,826
Day's Range N/A - N/A
Shares Out 1.78M
Stochastic %K 56%
Beta 1.19
Analysts Strong Buy
Price Target $40.00

Company Profile

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Hav...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 203 787 7888
Address:
4 Science Park, 3rd Floor, New Haven, United States
diddy48
diddy48 Apr. 24 at 9:12 PM
$PRPO this is a $1.40 pre split ..we have a lot of room to run.....
1 · Reply
SinnagodKosher
SinnagodKosher Apr. 22 at 10:46 PM
$PRPO smelling $30 👃
1 · Reply
Damadama
Damadama Apr. 17 at 12:58 PM
$PRPO
0 · Reply
Damadama
Damadama Apr. 17 at 12:57 PM
$PRPO oggi sopra 32
0 · Reply
imatisse
imatisse Apr. 16 at 2:23 PM
$PRPO
0 · Reply
Loren77
Loren77 Apr. 16 at 1:29 PM
$PRPO today, come on, we can feel it
0 · Reply
Awaywithshorts
Awaywithshorts Apr. 16 at 11:40 AM
$PRPO This is soooooo over due
0 · Reply
Rowdyreptile
Rowdyreptile Apr. 16 at 11:26 AM
$PRPO 🥚
0 · Reply
SinnagodKosher
SinnagodKosher Apr. 16 at 2:16 AM
$PRPO slow ride to the top baby 😎
0 · Reply
moola90
moola90 Apr. 15 at 10:47 PM
$PRPO one press release and this will fly
0 · Reply
Latest News on PRPO
Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Mar 12, 2026, 5:00 PM EDT - 6 weeks ago

Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year

Feb 25, 2026, 9:30 AM EST - 2 months ago

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year

Precipio Takes Major Steps Toward a Clean Balance Sheet

Jan 15, 2026, 9:00 AM EST - 3 months ago

Precipio Takes Major Steps Toward a Clean Balance Sheet

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

Dec 5, 2025, 10:00 AM EST - 5 months ago

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact

Dec 4, 2025, 8:00 AM EST - 5 months ago

Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact

Precipio Announces its Q3-2025 Financial Results

Nov 14, 2025, 4:30 PM EST - 5 months ago

Precipio Announces its Q3-2025 Financial Results

Precipio Announces Q3-2025 Shareholder Update Call

Nov 4, 2025, 5:00 PM EST - 6 months ago

Precipio Announces Q3-2025 Shareholder Update Call

Precipio Announces its Q2-2025 Financial Results

Aug 13, 2025, 5:00 PM EDT - 9 months ago

Precipio Announces its Q2-2025 Financial Results

Precipio Announces Q2-2025 Shareholder Update Call

Jul 31, 2025, 4:30 PM EDT - 9 months ago

Precipio Announces Q2-2025 Shareholder Update Call

Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless

Jul 11, 2025, 4:30 PM EDT - 10 months ago

Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless

Precipio Announces its Q1-2025 Financial Results

May 14, 2025, 5:00 PM EDT - 1 year ago

Precipio Announces its Q1-2025 Financial Results

Precipio Announces Q1-2025 Shareholder Update Call

May 1, 2025, 5:00 PM EDT - 1 year ago

Precipio Announces Q1-2025 Shareholder Update Call

Precipio Announces Q4 and year-end 2024 Shareholder Update Call

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Precipio Announces Q4 and year-end 2024 Shareholder Update Call

Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

Feb 25, 2025, 9:30 AM EST - 1 year ago

Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs

Jan 16, 2025, 5:00 PM EST - 1 year ago

Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs

Precipio Announces Q3-2024 Shareholder Update Call

Nov 6, 2024, 5:00 PM EST - 1 year ago

Precipio Announces Q3-2024 Shareholder Update Call

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

Oct 8, 2024, 10:00 AM EDT - 1 year ago

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

Precipio Announces Employee Stock Option Plan Repricing

Sep 6, 2024, 4:00 PM EDT - 1 year ago

Precipio Announces Employee Stock Option Plan Repricing

Precipio Announces Q2-2024 Shareholder Update Call

Aug 15, 2024, 5:00 PM EDT - 1 year ago

Precipio Announces Q2-2024 Shareholder Update Call

Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

Jul 25, 2024, 9:00 AM EDT - 1 year ago

Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

Jun 13, 2024, 4:00 PM EDT - 2 years ago

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Jun 12, 2024, 4:00 PM EDT - 2 years ago

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Precipio Secures a short-term $500K Credit Facility

May 6, 2024, 5:00 PM EDT - 2 years ago

Precipio Secures a short-term $500K Credit Facility

Precipio Announces Year end 2023 Shareholder Update Call

Mar 25, 2024, 5:00 PM EDT - 2 years ago

Precipio Announces Year end 2023 Shareholder Update Call

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

Feb 13, 2024, 10:00 AM EST - 2 years ago

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

Feb 6, 2024, 10:00 AM EST - 2 years ago

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Jan 23, 2024, 10:00 AM EST - 2 years ago

Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

Jan 17, 2024, 10:30 AM EST - 2 years ago

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

Precipio Announces Christina Valauri joins the Board of Directors

Jan 2, 2024, 9:00 AM EST - 2 years ago

Precipio Announces Christina Valauri joins the Board of Directors

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

Dec 14, 2023, 4:30 PM EST - 2 years ago

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

Precipio Announces Q3-2023 Shareholder Update Call

Nov 16, 2023, 5:00 PM EST - 2 years ago

Precipio Announces Q3-2023 Shareholder Update Call

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

Oct 18, 2023, 9:00 AM EDT - 2 years ago

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

Oct 3, 2023, 10:00 AM EDT - 2 years ago

Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

Precipio Continues to Sign New HemeScreen™ Customers

Sep 28, 2023, 9:00 AM EDT - 2 years ago

Precipio Continues to Sign New HemeScreen™ Customers

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

Sep 25, 2023, 11:00 AM EDT - 2 years ago

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Sep 21, 2023, 9:00 AM EDT - 2 years ago

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Sep 13, 2023, 9:30 AM EDT - 2 years ago

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Precipio Announces Q2-2023 Shareholder Update Call

Aug 10, 2023, 5:00 PM EDT - 2 years ago

Precipio Announces Q2-2023 Shareholder Update Call

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Aug 8, 2023, 9:00 AM EDT - 2 years ago

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Aug 3, 2023, 9:00 AM EDT - 2 years ago

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Aug 1, 2023, 9:00 AM EDT - 2 years ago

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

Jun 14, 2023, 9:49 AM EDT - 3 years ago

Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

Jun 13, 2023, 9:00 AM EDT - 3 years ago

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Jun 8, 2023, 8:30 AM EDT - 3 years ago

Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

Jun 7, 2023, 9:30 AM EDT - 3 years ago

Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

May 22, 2023, 11:00 AM EDT - 3 years ago

Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

Precipio Shares Growth Catalysts For HemeScreen

May 17, 2023, 4:00 PM EDT - 3 years ago

Precipio Shares Growth Catalysts For HemeScreen

Precipio Announces Q1-2023 Shareholder Update Call

May 15, 2023, 4:00 PM EDT - 3 years ago

Precipio Announces Q1-2023 Shareholder Update Call

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

May 4, 2023, 1:00 PM EDT - 3 years ago

Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

diddy48
diddy48 Apr. 24 at 9:12 PM
$PRPO this is a $1.40 pre split ..we have a lot of room to run.....
1 · Reply
SinnagodKosher
SinnagodKosher Apr. 22 at 10:46 PM
$PRPO smelling $30 👃
1 · Reply
Damadama
Damadama Apr. 17 at 12:58 PM
$PRPO
0 · Reply
Damadama
Damadama Apr. 17 at 12:57 PM
$PRPO oggi sopra 32
0 · Reply
imatisse
imatisse Apr. 16 at 2:23 PM
$PRPO
0 · Reply
Loren77
Loren77 Apr. 16 at 1:29 PM
$PRPO today, come on, we can feel it
0 · Reply
Awaywithshorts
Awaywithshorts Apr. 16 at 11:40 AM
$PRPO This is soooooo over due
0 · Reply
Rowdyreptile
Rowdyreptile Apr. 16 at 11:26 AM
$PRPO 🥚
0 · Reply
SinnagodKosher
SinnagodKosher Apr. 16 at 2:16 AM
$PRPO slow ride to the top baby 😎
0 · Reply
moola90
moola90 Apr. 15 at 10:47 PM
$PRPO one press release and this will fly
0 · Reply
MarInvestment
MarInvestment Apr. 15 at 6:23 PM
$PRPO break that $30 mark…
0 · Reply
imatisse
imatisse Apr. 15 at 3:21 PM
$PRPO Make it easy to make money. $40 $50 ….
0 · Reply
FOBtrader
FOBtrader Apr. 14 at 3:57 PM
$PRPO is it a scary thing that I have twice what’s the COO holds?!?!?
1 · Reply
Loren77
Loren77 Apr. 14 at 2:09 PM
$PRPO 30$ 🫩
0 · Reply
Loren77
Loren77 Apr. 13 at 2:07 PM
$PRPO Precipio Chief Operating Officer Sabet Ahmed Zaki reported purchase of 19 common shares at USD 27.93. * Holding rose to 1,034 common shares following transaction. 19... 🤦
1 · Reply
diddy48
diddy48 Apr. 12 at 2:29 PM
$PRPO https://www.tipranks.com/news/company-announcements/precipio-earnings-call-signals-profitable-growth-pivot
0 · Reply
SinnagodKosher
SinnagodKosher Apr. 8 at 2:39 PM
$PRPO yeeeeah, you’re growing to be a big strong stock yes? 😤🆙
0 · Reply
Loren77
Loren77 Apr. 8 at 12:08 PM
$PRPO 30+. NOW 😤
0 · Reply
Hellroaring
Hellroaring Apr. 7 at 7:47 PM
$PRPO ~ Kinda curious about a couple old (*really old*) tidbits ... all the current talk is about US market share, nothing about the EU or Asian markets, global market, etc 🤷‍♂️ With the connections the company has, it seems like that aspect should be a given; or maybe it is, but is deliberately being avoided as a talking point. 🧐
1 · Reply
FOBtrader
FOBtrader Apr. 7 at 2:51 PM
$PRPO He said he expects to take a larger share of the estimated market total of $500 million. Or another way to put it would be “grow market share” he gave zero guidance on how big that percentage could be. “We see significant opportunities to expand the share of our Products Division within an estimated $500 million addressable market annually in the U.S. ”
0 · Reply
Loren77
Loren77 Apr. 6 at 9:19 PM
$PRPO I recommend reading the full transcript of the conference. PRPO was an epic adventure, a huge challenge that seemed impossible to overcome... and yet we passed the critical point in 2025, and we have an extraordinary future full of projects and innovation. The competitive advantages that the world's best CEO and management have granted to their small company are astonishing. Don't be fooled by the $26.X price area; it's still very early to invest in PRPO; we're still an unknown microcap.
0 · Reply
imatisse
imatisse Apr. 6 at 7:22 PM
$PRPO ✈️✈️✈️
0 · Reply